Project Management Institute to Kick Off New Virtual Experience Series 29 July with Host Tamron Hall and Chef José Andrés
22.7.2020 16:30:00 EEST | Business Wire | Press release
Today Project Management Institute (PMI), the world's leading association for the project management profession, launched the new Virtual Experience Series to introduce professionals from all industries to innovative global voices and energize them to bring big ideas to life.
This groundbreaking new series, which is open to the public, connects participants with global innovators, inspirational voices and project leaders who will deliver 40 power-packed sessions to help those who want to boost their career or pivot to a new one. During the series, participants can connect with peers, mentors, experts and renowned public figures alike to gain insights on how to move their careers and projects forward and embrace the great potential and opportunity ahead of us.
Hosted by journalist, talk show host and executive producer Tamron Hall, the series’ six virtual experiences begin 29 July 2020 and continue through 9 December 2020. The first live 4.5-hour experience, titled “The Individual: My Work, My Life, My World” will feature renowned chef and humanitarian José Andrés; author and The New York Times podcast host Priya Parker; and more than 40 industry experts who will inspire, inform, engage and entertain.
During the opening session, José Andrés will discuss how he taps into his inner project manager to help feed the world. In 2010, he formed World Central Kitchen, a non-profit specializing in delivering food relief in the wake of natural and humanitarian disasters. World Central Kitchen has responded to dozens of disasters worldwide and distributed tens of millions of meals. In response to COVID-19, Andrés has partnered with restaurants, small farms and community leaders worldwide to combat food insecurity.
During the first-ever PMI Book Club, Bob Safian, podcast host and former Fast Company editor-in-chief, will chat with Priya Parker, author of “The Art of Gathering: How We Meet and Why it Matters.” Parker will share her inspired strategies for gathering global teams to get meaningful results from your virtual face-to-face meetings.
Each monthly experience will feature a new roster of celebrities and industry experts. Upcoming series dates and topics include:
● 29 July 2020 at 9 a.m. -1:30 p.m. EDT - The Individual: My Work, My Life, My World
● 25 August - The Community: Together We Rise
● 9 September - A Deep Dive in Organizational Agility: Adaptability, Resilience and Learning
● 20 October - The World: Our Global Impact
● 12 November - A Deep Dive in Business Analysis: Drawing a Map to the Future
● 9 December - The Future: Forging Our Path Forward
Registration for PMI members is $99 for a single experience or $359 for the entire series. Registration for non-members is $149 for a single experience or $899 for the event series. Purchasing a series pass includes complimentary on-demand access to PMI’s Talent and Technology Symposium, which took place in June. Each session is eligible for professional development units (PDUs) toward maintaining your PMI certification.
For more information on this event and to register, visit experience.pmi.org.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org, www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005274/en/
Contact information
Media Contact: Mary Ortega, mary.ortega@pmi.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom